Quick Order

Canine CD137 / 4-1BB / TNFRSF9 Protein (His Tag)

  • Canine CD137 / 4-1BB / TNFRSF9 Protein (His Tag) SDS-PAGE
DatasheetReviewsRelated ProductsProtocols
Canine 4-1BB/TNFRSF9 Protein Product Information
Synonym:TNFRSF9
Protein Construction:A DNA sequence encoding the canine TNFRSF9 (XP_850336.1) (Met1-Ser185) was expressed with a C-terminal polyhistidine tag.
Species:Canine
Expressed Host:Human Cells
Shipping:In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature.
Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise.
Canine 4-1BB/TNFRSF9 Protein QC Testing
Purity:> 95 % as determined by SDS-PAGE
Bio-Activity:Measured by its binding ability in a functional ELISA.
Immobilized canine TNFRSF9-His at 10 μg/ml (100 μl/well) can bind rat Fc-TNFSF9 (Cat:80166-R01H), The EC50 of rat Fc-TNFSF9 (Cat:80166-R01H) is 0.26-0.62 μg/ml.
Endotoxin:< 1.0 EU per μg of the protein as determined by the LAL method
Stability:Samples are stable for up to twelve months from date of receipt at -70℃
Predicted N Terminal:Ile 24
Molecule Mass:The recombinant canine TNFRSF9 comprises 173 amino acids and has a predicted molecular mass of 18.4 kDa. The apparent molecular mass of the protein is approximately 28-34 kDa in SDS-PAGE under reducing conditions due to glycosylation.
Formulation:Lyophilized from sterile PBS, pH 7.4.
1. Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA.
2. Please contact us for any concerns or special requirements.
Canine 4-1BB/TNFRSF9 Protein Usage Guide
Storage:Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Reconstitution:A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.
Canine 4-1BB/TNFRSF9 Protein SDS-PAGE
Canine CD137 / 4-1BB / TNFRSF9 Protein (His Tag) SDS-PAGE

4-1BB/TNFRSF9 Related Pathways

Other 4-1BB/TNFRSF9 Recombinant Protein Products
70095-D08H
4-1BB/TNFRSF9/CD137 Background

CD137 (also known as 4-1BB) is a surface co-stimulatory glycoprotein originally described as present on activated T lymphocytes, which belongs to the tumor necrosis factor (TNF) receptor superfamily. It is expressed mainly on activated CD4+ and CD8+ T cells, and binds to a high-affinity ligand (4-1BBL) expressed on several antigen-presenting cells such as macrophages and activated B cells. Upon ligand binding, 4-1BB is associated with the tumor necrosis factor receptor–associated factors (TRAFs), the adaptor protein which mediates downstream signaling events including the activation of NF-kappaB and cytokine production. 4-1BB signaling either by binding to 4-1BBL or by antibody ligation delivers signals for T-cell activation and growth, as well as monocyte proliferation and B-cell survival, and plays an important role in the amplification of T cell-mediated immune responses. In addition, CD137 and CD137L are expressed in different human primary tumor tissues, suggesting that they may influence the progression of tumors. Crosslinking of CD137 on activated T cells has shown promise in enhancing anti-tumor immune responses in murine models, and agonistic anti-CD137 antibodies are currently being tested in phase I clinical trials.

Immune Checkpoint
Immune Checkpoint Detection: Antibodies   Immune Checkpoint Detection: ELISA Antibodies
Immune Checkpoint Proteins
Immune Checkpoint Targets   Co-stimulatory Immune Checkpoint Targets

Immunotherapy   Cancer Immunotherapy   Targeted Therapy

Canine 4-1BB/TNFRSF9/CD137 References
  • Sica G, et al. (1999) Biochemical and immunological characteristics of 4-1BB (CD137) receptor and ligand and potential applications in cancer therapy. Arch Immunol Ther Exp (Warsz). 47(5): 275-9.
  • Nam KO, et al. (2005) The therapeutic potential of 4-1BB (CD137) in cancer. Curr Cancer Drug Targets. 5(5): 357-63.
  • Wang Q, et al. (2008) Analysis of CD137 and CD137L expression in human primary tumor tissues. Croat Med J. 49(2): 192-200.
  • Melero I, et al. (2008) Multi-layered action mechanisms of CD137 (4-1BB)-targeted immunotherapies. Trends Pharmacol Sci. 29(8): 383-90.
  • Thum E, et al. (2009) CD137, implications in immunity and potential for therapy. Front Biosci. 14: 4173-88.
  • Product nameProduct name
    Size / Price
    Catalog: 70095-D08H-100
    List Price: 
    Price:      (You Save: )
    Size:
    100 µg
    200 µg
    Quantity:+-
    AvailabilityIn Stock
    Add to CartBulk Discount Inquiry

    Datasheet & Documentation

    Contact Us
      Recently Viewed Items
        All information of our products is subject to change without notice. Please refer to COA enclosed in shipped package for the newest information.
        Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"